Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 7/20 | 0.52 |
| ▸ | CTSD | P07339 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15908799 | 1.00 | BACE1 (0.52) | BACE1BACE2CTSD | |
| SCHEMBL15900380 | 0.86 | BACE1 (0.58) | BACE1BACE2 | |
| SCHEMBL15900385 | 0.86 | BACE1 (0.58) | BACE1BACE2 | |
| SCHEMBL16479732 | 0.85 | BACE1 (0.59) | BACE1BACE2 | |
| SCHEMBL16462497 | 0.85 | BACE1 (0.48) | BACE1BACE2CTSD | |
| SCHEMBL16462138 | 0.85 | BACE1 (0.48) | BACE1BACE2CTSD | |
| SCHEMBL362269 | 0.83 | BACE1 (0.43) | BACE1BACE2CTSD | |
| SCHEMBL15900410 | 0.81 | BACE1 (0.68) | BACE1BACE2CTSD | |
| SCHEMBL15900408 | 0.81 | BACE1 (0.68) | BACE1BACE2CTSD | |
| SCHEMBL4082830 | 0.79 | BACE1 (0.43) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309263-B2 | Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof | AMGEN INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309263-B2 | Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof | AMGEN INC. (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2014120658-A1 | FUSED MULTICYCLIC 3-AMINO-5,6-DIHYDRO-2H-1,4-THIAZINE DERIVATIVES AND THEIR USE AS BETA-SECRETASE INHIBITORS | AMGEN INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| US-20140213581-A1 | FUSED MULTI-CYCLIC SULFONE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | AMGEN INC. | 2014-07-31 | — | — | US | disclosed |
| US-20140213581-A1 | FUSED MULTI-CYCLIC SULFONE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | AMGEN INC. | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213581-A1 | FUSED MULTI-CYCLIC SULFONE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.